Compare Merck & Co., Inc. (MRK) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Palantir Technologies Inc — how do they compare? Merck & Co., Inc. trades at $133.42 (market cap $321.77B), while Palantir Technologies Inc trades at $172.15 (market cap $420.39B). The key difference: Palantir Technologies Inc is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.61% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| MRK | PLTR | |
|---|---|---|
Market Cap | $321.77B | $420.39B |
Sector | Health | Technology |
52-Week High | $131.84 | $207.18 |
52-Week Low | $77.60 | $107.27 |
Enterprise Value | $368.53B | $411.19B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
PLTR trades at $170.50, down 2.68% today but maintains strong momentum with bullish moving averages and recent earnings beats. The company demonstrates exceptional financial performance with 84.8% gross margins and 49% net income margin, though valuation metrics remain elevated with P/E of 149.52. Recent news highlights conflicting institutional views with Cathie Wood selling while analysts maintain buy ratings.
Outlook remains positive with accelerating revenue growth and strong profitability, but high valuations and insider selling present risks. The consensus price target of $213.44 suggests 25% upside potential, though competition and market volatility could pressure the stock near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
